Kevin Feeley Sells 922 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 922 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $94.72, for a total transaction of $87,331.84. Following the sale, the chief financial officer now directly owns 5,446 shares in the company, valued at approximately $515,845.12. This trade represents a 14.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00.

GeneDx Stock Performance

NASDAQ WGS traded down $2.49 on Tuesday, reaching $87.17. 1,014,754 shares of the stock were exchanged, compared to its average volume of 607,372. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a one year low of $7.72 and a one year high of $115.60. The company’s 50-day simple moving average is $83.51 and its two-hundred day simple moving average is $68.32. The firm has a market capitalization of $2.45 billion, a PE ratio of -44.47 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. The business had revenue of $95.64 million for the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the topic of a number of recent research reports. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. TD Cowen lifted their price objective on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $72.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of WGS. Vanguard Group Inc. boosted its position in GeneDx by 18.5% in the 4th quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock valued at $77,337,000 after buying an additional 156,768 shares during the period. Summit Partners Public Asset Management LLC boosted its position in GeneDx by 336.9% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock valued at $58,073,000 after purchasing an additional 582,619 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in GeneDx in the fourth quarter valued at approximately $51,496,000. Lord Abbett & CO. LLC purchased a new stake in GeneDx in the fourth quarter valued at about $48,458,000. Finally, Fred Alger Management LLC boosted its stake in GeneDx by 38.5% in the 4th quarter. Fred Alger Management LLC now owns 546,054 shares of the company’s stock worth $41,970,000 after purchasing an additional 151,824 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.